IFPMA revamps code of conduct to "do the right thing" in industry
This article was originally published in SRA
The IFPMA, which represents the global pharmaceutical industry, particularly in its dealings with UN bodies such as the World Health Organisation, has updated its code of conduct to take account of changes to national industry codes and issues relating to ethical and professional standards around the world1,2. The association says the revamped code, when it comes into effect in September, will provide an "effective framework for ethical business practices".
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.